Galena Biopharma, Inc. (GALE)
-NasdaqCM 2.43 
0.07(2.80%) May 17, 4:00PM EDT|After Hours
:
2.44 0.01 (0.41%) May 17, 7:59PM EDT
| Prev Close: | 2.50 |
|---|
| Open: | 2.54 |
|---|
| Bid: | 2.25 x 2000 |
|---|
| Ask: | 2.85 x 100 |
|---|
| 1y Target Est: | 4.94 |
|---|
| Beta: | 1.59 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.43 - 2.54 |
|---|
| 52wk Range: | 1.17 - 3.00 |
|---|
| Volume: | 1,549,849 |
|---|
| Avg Vol (3m): | 2,124,890 |
|---|
| Market Cap: | 201.69M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.27 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- A Journey To Add Biotech To The Portfolioat Seeking Alpha(Sat, May 18)
- GALENA BIOPHARMA, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- GALENA BIOPHARMA, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and ExEDGAR Online(Thu, May 16)
- Galena Targets Cancer Pain Marketat Seeking Alpha(Wed, May 15)
- Alexza Pharmaceuticals: A Teva Partnership Of Immense Meaningat Seeking Alpha(Wed, May 15)
- Galena Biopharma: Stock First, Science Second?at Seeking Alpha(Mon, May 13)
- VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial ResultsGlobeNewswire(Thu, May 9)
- GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExEDGAR Online(Thu, May 9)
- Galena Biopharma's Abstral serves as model for TIRF REMS programtheflyonthewall.com(Thu, May 9)
- Galena Biopharma Poster Presentation at the American Pain Society 32nd Annual Scientific MeetingGlobeNewswire(Thu, May 9)
- Galena: Improving Cancer Vaccines for the Futureat Motley Fool(Tue, May 7)
- Top Small-Cap Biotech Stocks Being Accumulated By Large Fund Managersat Seeking Alpha(Tue, May 7)
- 2 Biotechs To Avoid, 1 To Buyat Motley Fool(Sat, May 4)
- 3 Stocks Near 52-Week Highs Worth Sellingat Motley Fool(Thu, May 2)
- GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibiEDGAR Online(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.38 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.10 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing oncology treatments to address major unmet medical needs to advance cancer care.
View More